Hepatitis C virus (HCV) infects over 170 million people worldwide and can lead to cirrhosis, liver failure, and liver cancer. The current medications that we have for the treatment of hepatitis are imperfect.
Finding better drugs for the treatment of HCV is therefore a priority. The study of factors that regulate the viral lifecycle, of which host lipid biosynthesis is one, can help us better understand the virus to combat infection.
The identification of biomarkers prognositic of outcome in chronic HCV infection can help guide therapeutic decision making. The examination of the mechanism of action of our anti-viral compounds can not only be used as a method to characterize key interactions and pathways critical to viral replication, but can be a productive means to the discovery of potential antiviral agents for the treatment of chronic HCV infection.